• Publications
  • Influence
EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.
The 5-HT1A receptor agonist 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT; 0.55 mg/kg s.c.) and the 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor/5-HT1A receptor ligandExpand
A pharmacological profile of the novel, peripherally‐selective k‐opioid receptor agonist, EMD 61753
1 The pharmacological properties of the novel diarylacetamide k‐opioid receptor agonist, EMD 61753, have been compared with those of ICI 197067 (a centrally‐acting k agonist) and ICI204448 (aExpand
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Vilazodone has been reported to be an inhibitor of 5-hydoxytryptamine (5-HT) reuptake and a partial agonist at 5-HT1A receptors. Using [35S]GTPgammaS binding in rat hippocampal tissue, vilazodone wasExpand
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Dyskinesia is an important complication of treatment in Parkinson's disease (PD). Sarizotan, a 5-HT(1A) agonist with high affinity for D3 and D4 receptors was investigated on L-Dopa-inducedExpand
Effects of sarizotan on the corticostriatal glutamate pathways
The effects of sarizotan, a 5‐HT1A agonist with additional affinity for D3 and D4 receptors, have been studied on the corticostriatal glutamate pathways using dual‐probe microdialysis in the awakeExpand
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
RationaleDyskinesia affects the majority of levodopa-treated parkinsonian patients within 5–10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase inExpand
Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile
Summary.Sarizotan exhibited high affinities only to serotonin 5-HT1A receptors and dopamine DA D4>D3>D2 receptors with the profile of a 5-HT1A agonist and DA antagonist demonstrated by the inhibitionExpand
The highly selective 5‐hydroxytryptamine (5‐HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced
We examined the effect of the highly selective 5‐hydroxytryptamine (5‐HT)2A receptor antagonist 7‐{4‐[2‐(4‐fluoro‐phenyl)‐ethyl]‐piperazine‐1‐carbonyl}‐1H‐indole‐3‐carbonitrile HCl (EMD 281014) inExpand
EMD 281014, a new selective serotonin 5-HT2A receptor antagonist.
The 5-HT2A receptor ligand 7-[4-[2-(4-fluoro-phenyl)-ethyl]-piperazine-1-carbonyl]-1H-indole-3-carbonitrile HCl (EMD 281014) selectively binds to human (h) and rat 5-HT2A receptors (IC50 values 0.35Expand
Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats.
We examined the effect of Vilazodone, a selective serotonin reuptake inhibitor (SSRI) and serotonin 1A (5-HT(1A)) receptor agonist [Bartoszyk, G.D., Hegenbart, R., Ziegler, H., 1997. EMD 68843, aExpand